Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely match the label for drospirenone identity/class and composition where explicitly described, but it includes two additional statements about generic listing/formulary practices that are not supported by the provided label excerpts. Also, the evaluation does not address many safety-critical label sections, limiting overall labeling alignment assessment.
Category Scores
Accurate Statements
Slynd’s generic name is drospirenone.
11 DESCRIPTION: "SLYND (drospirenone) is for use as an oral contraceptive."
Drospirenone is a progestin used in oral contraception.
11 DESCRIPTION: "SLYND (drospirenone) is for use as an oral contraceptive."; 11 DESCRIPTION: "Drospirenone ... It is a progestin..."
The active ingredient across Slynd products is drospirenone.
11 DESCRIPTION: "each holding ... tablets each containing 4 mg of drospirenone"; "The active tablet ... contains 4mg of drospirenone as the active ingredient"
Unsupported Statements
Generic versions of Slynd, when available, list drospirenone as the generic drug name.
Not supported by the provided FDA label excerpts; the excerpts do not state how generic versions are listed or that generic products exist with that listing.
In the U.S., prescription drug labels and formularies typically list the generic name as drospirenone even if the product is sold under the brand name Slynd.
Not supported by the provided FDA label excerpts; this is a general U.S. listing/formulary practice statement not addressed in the supplied label text.
Contradictions
Important Omissions
No assessment of safety-critical FDA label sections (e.g., boxed warning, contraindications, warnings/precautions, dosage and administration, and use in specific populations) was performed; therefore overall label alignment for safety content cannot be determined from the provided excerpts/evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated unsupported items are primarily regulatory/listing practice claims (not dosing, contraindications, or specific safety recommendations). The label-aligned items are identity/composition/class claims, which generally have low immediate patient-risk impact compared with omissions in contraindications/dosing sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two claims about generic product naming/listing and U.S. formulary/labeling practices are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to what the supplied FDA label text explicitly supports (e.g., identity/composition and the indication). Remove or rephrase generic/formulary listing practice claims unless supported by the relevant FDA label sections provided.